Cargando…

Disruption of the Interaction of RAS with PI 3-Kinase Induces Regression of EGFR-Mutant-Driven Lung Cancer

RAS family GTPases contribute directly to the regulation of type I phosphoinositide 3-kinases (PI3Ks) via RAS-binding domains in the PI3K catalytic p110 subunits. Disruption of this domain of p110α impairs RAS-mutant-oncogene-driven tumor formation and maintenance. Here, we test the effect of blocki...

Descripción completa

Detalles Bibliográficos
Autores principales:	Murillo, Miguel M., Rana, Sareena, Spencer-Dene, Bradley, Nye, Emma, Stamp, Gordon, Downward, Julian
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Cell Press 2018
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6315106/ https://www.ncbi.nlm.nih.gov/pubmed/30590030 http://dx.doi.org/10.1016/j.celrep.2018.12.003

Ejemplares similares

Requirement for Interaction of PI3-Kinase p110α with RAS in Lung Tumor Maintenance
por: Castellano, Esther, et al.
Publicado: (2013)

Oncogenic RAS Signaling Promotes Tumor Immunoresistance by Stabilizing PD-L1 mRNA
por: Coelho, Matthew A., et al.
Publicado: (2017)

YAP1 and TAZ Control Pancreatic Cancer Initiation in Mice by Direct Up-regulation of JAK–STAT3 Signaling
por: Gruber, Ralph, et al.
Publicado: (2016)

RAC1(P29S) Induces a Mesenchymal Phenotypic Switch via Serum Response Factor to Promote Melanoma Development and Therapy Resistance
por: Lionarons, Daniël A., et al.
Publicado: (2019)

JunD, not c-Jun, is the AP-1 transcription factor required for Ras-induced lung cancer
por: Ruiz, E. Josue, et al.
Publicado: (2021)

FBXW7 mutations typically found in human cancers are distinct from null alleles and disrupt lung development
por: Davis, Hayley, et al.
Publicado: (2011)

Combined targeting of G protein‐coupled receptor and EGF receptor signaling overcomes resistance to PI3K pathway inhibitors in PTEN‐null triple negative breast cancer
por: Zecchin, Davide, et al.
Publicado: (2020)

Argonaute 2 modulates EGFR–RAS signaling to promote mutant HRAS and NRAS-driven malignancies
por: Siebenaler, Ronald F, et al.
Publicado: (2022)

RAS and RHO Families of GTPases Directly Regulate Distinct Phosphoinositide 3-Kinase Isoforms
por: Fritsch, Ralph, et al.
Publicado: (2013)

Putative direct and indirect Wnt targets identified through consistent gene expression changes in APC-mutant intestinal adenomas from humans and mice
por: Segditsas, Stefania, et al.
Publicado: (2008)

YAP drives cutaneous squamous cell carcinoma formation and progression
por: Vincent-Mistiaen, Zoé, et al.
Publicado: (2018)

RAF inhibitor PLX8394 selectively disrupts BRAF-dimers and RAS-independent BRAF mutant-driven signaling
por: Yao, Zhan, et al.
Publicado: (2018)

Transient Disappearance of RAS Mutant Clones in Plasma: A Counterintuitive Clinical Use of EGFR Inhibitors in RAS Mutant Metastatic Colorectal Cancer
por: Raimondi, Cristina, et al.
Publicado: (2019)

Undetectable RAS-Mutant Clones in Plasma: Possible Implication for Anti-EGFR Therapy and Prognosis in Patients With RAS-Mutant Metastatic Colorectal Cancer
por: Bouchahda, Mohamed, et al.
Publicado: (2020)

RAS signalling through PI3-Kinase controls cell migration via modulation of Reelin expression
por: Castellano, Esther, et al.
Publicado: (2016)

Duct- and Acinar-Derived Pancreatic Ductal Adenocarcinomas Show Distinct Tumor Progression and Marker Expression
por: Ferreira, Rute M.M., et al.
Publicado: (2017)

Drugging the Undruggable: Advances on RAS Targeting in Cancer
por: Molina-Arcas, Miriam, et al.
Publicado: (2021)

Direct targeting of oncogenic RAS mutants with a tumor-specific cytosol-penetrating antibody inhibits RAS mutant–driven tumor growth
por: Shin, Seung-Min, et al.
Publicado: (2020)

A Drosophila Model for EGFR-Ras and PI3K-Dependent Human Glioma
por: Read, Renee D., et al.
Publicado: (2009)

Ras and TGFβ cooperatively regulate epithelial cell plasticity and metastasis: dissection of Ras signaling pathways
por: Janda, Elzbieta, et al.
Publicado: (2002)

Novel zinc-based fixative for high quality DNA, RNA and protein analysis
por: Lykidis, Dimitrios, et al.
Publicado: (2007)

Identification of RAS mutant biomarkers for EGFR inhibitor sensitivity using a systems biochemical approach
por: McFall, Thomas, et al.
Publicado: (2021)

RAS nucleotide cycling underlies the SHP2 phosphatase dependence of mutant BRAF-, NF1- and RAS-driven cancers
por: Nichols, Robert J., et al.
Publicado: (2018)

Clinical impact of subclonal EGFR T790M mutations in advanced-stage EGFR-mutant non-small-cell lung cancers
por: Vaclova, Tereza, et al.
Publicado: (2021)

Efficient Genotyping of KRAS Mutant Non-Small Cell Lung Cancer Using a Multiplexed Droplet Digital PCR Approach
por: Pender, Alexandra, et al.
Publicado: (2015)

Delta1 Expression, Cell Cycle Exit, and Commitment to a Specific Secretory Fate Coincide within a Few Hours in the Mouse Intestinal Stem Cell System
por: Stamataki, Despina, et al.
Publicado: (2011)

Activated R-Ras, Rac1, Pi 3-Kinase and Pkcε Can Each Restore Cell Spreading Inhibited by Isolated Integrin β1 Cytoplasmic Domains
por: Berrier, Allison L., et al.
Publicado: (2000)

EGFRAP encodes a new negative regulator of the EGFR acting in both normal and oncogenic EGFR/Ras-driven tissue morphogenesis
por: Soler Beatty, Jennifer, et al.
Publicado: (2021)

SHOC2 phosphatase-dependent RAF dimerization mediates resistance to MEK inhibition in RAS-mutant cancers
por: Jones, Greg G., et al.
Publicado: (2019)

Monitoring of RAS mutant clones in plasma of patients with RAS mutant metastatic colorectal cancer
por: Fernández Montes, A., et al.
Publicado: (2022)

Genomic Determinants of PI3K Pathway Inhibitor Response in Cancer
por: Weigelt, Britta, et al.
Publicado: (2012)

Co-targeting KRAS G12C and EGFR reduces both mutant and wild-type RAS-GTP
por: McFall, Thomas, et al.
Publicado: (2022)

Efficacy of rigosertib, a small molecular RAS signaling disrupter for the treatment of KRAS-mutant colorectal cancer
por: Zhou, Xinyi, et al.
Publicado: (2022)

Clonal dynamics of BRAF-driven drug resistance in EGFR-mutant lung cancer
por: Schaufler, Diana, et al.
Publicado: (2021)

Osimertinib Regresses an EGFR-Mutant Cisplatinum- Resistant Lung Adenocarcinoma Growing in the Brain in Nude Mice
por: Higuchi, Takashi, et al.
Publicado: (2019)

Targeting the PI3K/Akt pathway in murine MDS/MPN driven by hyperactive Ras
por: Akutagawa, Jon, et al.
Publicado: (2016)

Phosphorylated EGFR Dimers Are Not Sufficient to Activate Ras
por: Liang, Samantha I., et al.
Publicado: (2018)

Acquired RAS or EGFR mutations and duration of response to EGFR blockade in colorectal cancer
por: Van Emburgh, Beth O., et al.
Publicado: (2016)

Emerging Molecular Dependencies of Mutant EGFR-Driven Non-Small Cell Lung Cancer
por: Farnsworth, Dylan A., et al.
Publicado: (2021)

Syringin exerts anti-breast cancer effects through PI3K-AKT and EGFR-RAS-RAF pathways
por: Wang, Fei, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_i6o43eep1nmtu3kv86731bu86p